Jack Wright

1009 Phase II clinical experience with the novel proteasome inhibitor bortezomib (formerly PS-341) in patients with indolent and mantle cell lymphomas

A. Zelenetz, O. O’Connor, D. Schenkein, 2003 .

The EBV-Encoded Oncoprotein, LMP1, Induces an Epithelial-to-Mesenchymal Transition (EMT) via Its CTAR1 Domain through Integrin-Mediated ERK-MAPK Signalling

Mhairi A. Morris, L. Young, Mhairi A Morris, 2018, Cancers.

Schedule of bortezomib administration may be an important determinant of single-agent activity in patients with relapsed or refractory follicular (FL) lymphoma and mantle cell lymphoma (MCL)

C. Moskowitz, O. O’Connor, P. Hamlin, 2007 .

A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401)

S. Phuphanich, T. Batchelor, M. Chamberlain, 2007 .

Clinical Trials in Ovarian Cancer, Part 2

M. Christian, E. Trimble, T. Cornelison, 2002 .